Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 6/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 6/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386934 | 0.94 | S1PR1 (0.43) | S1PR1S1PR3S1PR5LMNAALDH1A1 | |
| SCHEMBL5657253 | 0.82 | S1PR1 (0.47) | S1PR1S1PR3S1PR5LMNAMAPT | |
| SCHEMBL383331 | 0.81 | S1PR1 (0.55) | S1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL5658171 | 0.81 | S1PR1 (0.46) | S1PR1S1PR3S1PR5LMNAMAPT | |
| Oxalic Acid SCHEMBL386933 | 0.80 | S1PR1 (0.38) | S1PR1S1PR3S1PR5LMNAALDH1A1 | |
| SCHEMBL387022 | 0.79 | GRM5 (0.37) | S1PR1S1PR3S1PR5GRM5 | |
| SCHEMBL386909 | 0.77 | S1PR1 (0.44) | S1PR1S1PR3S1PR5S1PR4GRM5 | |
| SCHEMBL387857 | 0.76 | FFAR1 (0.36) | FFAR1FFAR4LMNAMAPTALDH1A1 | |
| SCHEMBL3195967 | 0.76 | S1PR1 (0.42) | S1PR1S1PR3S1PR5LMNA | |
| SCHEMBL384555 | 0.74 | CXCR2 (0.38) | S1PR1S1PR3S1PR5ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199150-B2 | Amino alcohol compounds | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | SANKYO COMPANY, LIMITED (JP) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043386-A1 | Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these | PHOSPHO1, CD4, FCGRT | S1PR1 257/4885S1PR3 414/4885S1PR5 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.